清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

阶段(地层学) 肿瘤科 临床试验 IGHV@ 生存分析 化学免疫疗法 比例危险模型 危险系数 队列 临床研究阶段 累积发病率
作者
Manuela Bergmann,Raymonde Busch,Barbara Eichhorst,Andreas Buehler,Norbert Fischer,Michael J. Eckart,Ursula Vehling-Kaiser,Ulrich Jäger,Georg Hopfinger,Clemens M. Wendtner,Kirsten Fischer,Bertold Emmerich,Hartmut Döhner,Michael Hallek,Stephan Stilgenbauer
出处
期刊:Blood [American Society of Hematology]
卷期号:122 (21): 4127-4127 被引量:4
标识
DOI:10.1182/blood.v122.21.4127.4127
摘要

Introduction Chronic lymphocytic leukemia (CLL) is typically diagnosed at an early stage and a watch & wait (W&W) strategy is applied. Only when the disease progresses to a more active, symptomatic form, treatment is indicated. The prospective CLL1 trial was designed to evaluate the benefit of early risk-adapted therapy with fludarabine (F) monotherapy, and to document the natural course of the disease from diagnosis. Here we present follow-up data to assess overall survival from the time point of treatment indication. Methods At enrolment, risk stratification was performed based on bone marrow (BM) infiltration pattern, lymphocyte doubling time (LDT), serum beta2-microglobulin (s2-MG), and serum thymidine kinase (TK). Pts were “high-risk” (HR) if they had diffuse BM infiltration pattern and/or LDT 7.0 U/L and/or s2-MG >3.5 mg/L at enrolment. HR pts were randomized in a 1:1 ratio to early F (HR-F), or to W&W until classical treatment indication (HR-W&W), which was also applied to all low-risk (LR) pts. Results Between 1997 and 2004, 710 pts with Binet A stage CLL were enrolled and underwent risk stratification (RS) per protocol. Median time from diagnosis to enrolment was 3.2 mo (range 0-33.7) and median follow-up time was 8.5 years (yrs) (range 0-13.9). 521 pts (73%) were stratified to LR and 189 pts (27%) to HR, of whom 93 pts (49%) were randomized to HR-F and 96 pts (51%) to HR-WW high-risk cytogenetic features (17p- and 11q-) had 3% and 8% of pts, respectively. Early intervention with F among HR pts significantly prolonged progression-free survival (PFS) (30 vs. 13 mo; p 3.5 mg/L, and age >60 yrs as independent prognostic factors for OS for patients with progressive, active disease and treatment indication. Conclusions Monotherapy with fludarabine is not superior to the W&W approach for the management of early stage CLL pts, since early F did not improve OS or outcome following subsequent therapies. Disclosures: No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gmc完成签到 ,获得积分10
8秒前
搬砖的化学男完成签到 ,获得积分0
23秒前
31秒前
36秒前
zw完成签到,获得积分10
52秒前
刘辰完成签到 ,获得积分10
1分钟前
wxyinhefeng完成签到 ,获得积分10
1分钟前
打打应助舒心的南珍采纳,获得10
1分钟前
MOF完成签到 ,获得积分10
1分钟前
糖宝完成签到 ,获得积分10
1分钟前
我睡觉的时候不困完成签到 ,获得积分10
1分钟前
小马甲应助xun采纳,获得10
1分钟前
1分钟前
有魅力荟发布了新的文献求助10
1分钟前
缥缈的闭月完成签到,获得积分10
2分钟前
echo完成签到 ,获得积分10
2分钟前
回首不再是少年完成签到,获得积分0
2分钟前
jasmine完成签到 ,获得积分10
2分钟前
吉祥高趙完成签到 ,获得积分10
3分钟前
小小果妈完成签到 ,获得积分10
3分钟前
奶糖喵完成签到 ,获得积分10
3分钟前
hbuhfl完成签到 ,获得积分10
3分钟前
一彤展翅完成签到,获得积分10
3分钟前
3分钟前
xun发布了新的文献求助10
3分钟前
ally完成签到,获得积分10
3分钟前
li完成签到 ,获得积分10
4分钟前
kenchilie完成签到 ,获得积分10
4分钟前
属实有点拉胯完成签到 ,获得积分10
4分钟前
apckkk完成签到 ,获得积分10
4分钟前
4分钟前
SciKid524完成签到 ,获得积分10
4分钟前
chemlixy完成签到 ,获得积分10
5分钟前
cstp完成签到,获得积分10
5分钟前
mark33442完成签到,获得积分10
5分钟前
小美酱完成签到 ,获得积分10
5分钟前
淡然藏花完成签到 ,获得积分10
5分钟前
苏su完成签到 ,获得积分10
5分钟前
完美梨愁完成签到 ,获得积分10
5分钟前
苗条的小蜜蜂完成签到 ,获得积分10
5分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571317
求助须知:如何正确求助?哪些是违规求助? 3141926
关于积分的说明 9444838
捐赠科研通 2843331
什么是DOI,文献DOI怎么找? 1562830
邀请新用户注册赠送积分活动 731326
科研通“疑难数据库(出版商)”最低求助积分说明 718524